Although this class of mutations is associated with poorer response to first-, second- and third-generation EGFR TKIs compared to classical EGFR mutations, a number of next-generation EGFR targeted agents have recently been approved for the treatment of NSCLC tumours harbouring Ex20ins or are currently undergoing clinical evaluation [79,80,82,84]. Here, EGFR is linked to neoplasm.